MediBeacon completes trial of transdermal glomerular filtration rate monitor

Cara Livernois | | Health Exec | Precision Medicine

MediBeacon, a company within the Pansend Life Sciences platform of HC2 Holdings, has released the results of a clinical trial testing the effectiveness of its Transdermal Glomerular Filtration Rate ("GFR") Monitor on patients with ranging kidney function.

Moving toward real-time measurements, the monitor uses optical skin sensors with a fluorescent tracer agent that glows under light. This device is able to give physicians continuous measurements of kidney function without the need to take blood.

"Completion of our clinical study on patients with impaired kidney function represents an important milestone," said Steve Hanley, MediBeacon CEO.  "We anticipate beginning our multicenter clinical study including sites in the United States and Europe during the fourth quarter 2017."

"Methods to assess kidney function have not changed in 25 years," said Richard Solomon, a professor at the University of Vermont College of Medicine.  "MediBeacon's point of care system could represent a major breakthrough in measuring kidney function."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”